The trace-amine associated receptor-1 (TAAR1) is a member of the G-protein coupled receptor (GPCR) receptor family and is widely distributed across the brain and gastrointestinal system and functions in a variety of neuronal processes [1,2,3]. A range of endogenous trace amines (TA) activate TAAR1 signalling pathways through G protein subtypes [3]. Several neuropsychiatric disorders, including schizophrenia, depression, drug addiction, attention deficit hyperactive disorder (ADHD) and metabolic disorders are associated with TAAR1 [3,4,5]. An emerging new class of antipsychotic agents, TAAR1 agonists, show promise for treating schizophrenia (Ulotaront – US FDA Breakthrough therapy status) and other neuropsychiatric conditions [5].

微量胺相关受体-1 （TAAR1） 是 G 蛋白偶联受体 （GPCR） 受体家族的一员，广泛分布在大脑和胃肠道系统中，并在多种神经元过程中发挥作用 [1,2,3]。一系列内源性痕量胺 （TA） 通过 G 蛋白亚型激活 TAAR1 信号通路 [3]。TAAR1 与多种神经精神疾病有关，包括精神分裂症、抑郁症、药物成瘾、注意力缺陷多动障碍 （ADHD） 和代谢紊乱 [3,4,5]。一类新兴的新型抗精神病药物TAAR1激动剂显示出治疗精神分裂症（Ulotaront-美国FDA突破性疗法状态）和其他神经精神疾病的前景[5]。